Tecentriq did not meet the primary end point in a postmarketing study as a first-line treatment.
Formulary Watch
Latest News
All News
Advertisement
The update indicates there is a serious risk of dehydration and is contraindicated in children.
Bluebook Rx is a new solution that helps employers and plan sponsors better understand and optimize their prescription drug spending.
Tibsovo is the first targeted therapy for IDH1-mutated cholangiocarcinoma, a cancer of the bile ducts within and outside the liver.
Developed by Ascendis Pharma, this is the first therapy that delivers growth hormone over one week.
ICER’s policy recommendations suggest payers establish step therapy with less expensive systemic agents to allow patients and clinicians to choose from multiple options.
The liquid therapy to treat hypothyroidism now comes in 15 different dosage strengths in single-use packaging.
Xarelto is now indicated to help reduce the risks of major cardiovascular events in patients with coronary artery disease and major thrombotic vascular events.
Preliminary research shows Anplag could be repurposed as a heart failure treatment at a lower cost.
Now called Comirnaty, the vaccine is approved for those 16 years and older.
Advertisement
The FDA has set a PDUFA date of December 23, 2021.
Generics of Chantix, Durezol, Eliquis, and injection potassium/sodium are approved while generics of Tegretol and Levophed are launched.
The therapy is the first approved for patients with tumors associated with von Hippel-Lindau disease.
The report found that mavacamten offers benefits but was above the threshold of $150,000 per quality-adjusted life-years.
These results can be used to inform health care decisions, but investigators caution there hasn’t been head-to-head trials of the two therapies.
Including patients in the decision-making process, the authors said, is an important component of patient-centered health care.
The monoclonal antibody had been given an emergency use authorization to treat COVID-19, but the recent spike in cases is driving a shortage in supply.
The move, effective July 15, was the result of a generic now being available.
A total of 16 lots have been recalled.
The therapy is expected to be available by early September.
Effective January 2023, the organization will switch from Express Scripts to CVS Caremark.
This vaccine protects against tick-borne encephalitis in people over the age of 1 year.
The multiple myeloma therapy now has a permanent J code under Medicare Part B.
Trials result show that Lyumjev compares favorably to Humalog.
All stakeholders together incur about $93.3 billion in costs for implementing, contesting, and navigating drug utilization management.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA Reviewing New Combination Therapy for Patients with MIBC
2
A Conversation With Lucille Accetta, RPh, M.P.H., MBA
3
U.S. Lung Cancer Survival Improves to Nearly 30%, but Funding Cuts Threaten Progress
4
Selling Direct
5
